|
Adenocarcinoma
|
0.300 |
Biomarker
|
group |
CTD_human |
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
|
14991579 |
2004 |
|
Pancreatic Neoplasm
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
|
14991579 |
2004 |
|
Adenocarcinoma, Basal Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
|
14991579 |
2004 |
|
Adenocarcinoma, Oxyphilic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
|
14991579 |
2004 |
|
Carcinoma, Cribriform
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
|
14991579 |
2004 |
|
Carcinoma, Granular Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
|
14991579 |
2004 |
|
Adenocarcinoma, Tubular
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
|
14991579 |
2004 |
|
Malignant neoplasm of pancreas
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
|
14991579 |
2004 |
|
Vital capacity
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Importantly, we discovered that the membrane localization of SCP1 is crucial for impeding angiogenesis and tumor growth, and this localization depends on palmitoylation of a conserved cysteine motif within its NH2 terminus.
|
28440748 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Collectively, our findings indicate that SCP1 is a potential tumor suppressor for liver cancers through dephosphorylating c-Myc Ser62.
|
25893300 |
2016 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Furthermore, blocking PML degradation in ccRCC by SCP1 overexpression or Pin1 inhibition enhanced the tumor-suppressive effects of the mTOR inhibitor temsirolimus.
|
25293974 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
SCP-1 was found in only one specimen and a several antigens could not been detected in any tumor tissue or cell line (MAGE-B, GAGE-1,2,8 and all 4 RAGE genes).
|
12584747 |
2003 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The SCP-1-like gene and cTAGE-1 were shown to be immunogenic and immunologically tumor-specific and may therefore be candidates for immunotherapy targeting CTCL.
|
11149944 |
2001 |
|
Malignant neoplasm of testis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In 98 evaluable cases, SCP-1 and SSX-4 were expressed most frequently (both 65%), followed by HOM-TES-85/CT-8 (47%), GAGE (26%), SSX-1 (20%), NY-ESO-1 (13%), MAGE-3 (11%), SSX-2 (8%), CT-10 (7%), MAGE-4 (4%) and CT-7 (1%).
|
16094643 |
2006 |
|
Malignant neoplasm of testis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
To shed light on the epigenetic phenotypes among histological subtypes of TGCTs, we investigated the methylation and expression of several cancer testis antigen (CTA) genes (MAGEA1, MAGEA3, and SYCP1) in TGCTs.
|
15672408 |
2005 |
|
Malignant neoplasm of testis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In order to define antigens that might be suitable as vaccines for pancreatic carcinoma, we investigated the composite expression of 10 cancer testis (CT) antigens (SCP-1, NY-ESO-1, SSX-1, SSX-2, SSX-4, GAGE, MAGE-3, MAGE-4, CT-7 and CT-8) by Reverse Transcriptase-PCR (RT-PCR) in fresh biopsies of human pancreatic adenocarcinoma, chronic pancreatitis and pancreatic carcinoma cell lines.
|
14991579 |
2004 |
|
Lymphoma, T-Cell, Cutaneous
|
0.020 |
Biomarker
|
disease |
BEFREE |
SCP-1 might serve as an additional diagnostic indicator in early and clinically indistinct lesions suspicious for cutaneous T-cell lymphoma.
|
11807795 |
2002 |
|
Lymphoma, T-Cell, Cutaneous
|
0.020 |
Biomarker
|
disease |
BEFREE |
The SCP-1-like gene and cTAGE-1 were shown to be immunogenic and immunologically tumor-specific and may therefore be candidates for immunotherapy targeting CTCL.
|
11149944 |
2001 |
|
Hyperglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
SCP-1 and SCP-2 also increased the activities of glutathione peroxidase (GSH-Px), catalase (CAT) and superoxide dismutase (SOD), as well as decreased the content of malondialdehyde (MDA) in the hyperglycemia mice.
|
30529353 |
2019 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
SYCP1 genes exist as large multi-exonic genes in most animals.
|
29297095 |
2018 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Thus, our study discovers a novel mechanism underlying SCP1 shuttling between the plasma membrane and nucleus, which constitutes a unique pathway in transducing AKT signaling that is closely linked to angiogenesis and tumorigenesis.
|
28440748 |
2017 |
|
SVEINSSON CHORIORETINAL ATROPHY
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this study, we obtained the full-length sequence of the SCP gene from R. similis (Rs-scp-1), which is 1665 bp long and includes a 1461-bp open reading frames encoding 486 amino acids with an 18-aa signal peptide.
|
28684768 |
2017 |
|
Malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings indicate that SCP1 is a potential tumor suppressor for liver cancers through dephosphorylating c-Myc Ser62.
|
25893300 |
2016 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Primary MSCs as well as a MSC line (SCP-1) were cocultured with primary breast cancer cells, MCF-7, MDA-MB231 breast carcinoma or MCF-10A non-malignant breast epithelial cells or their conditioned medium.
|
24806942 |
2015 |